PARP1-siRNA suppresses human prostate cancer cell growth and progression.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Oncology Report

• Publication date

  2018-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3892/or.2018.6238PMID 29393407
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Dual Approaches in Oncology: The Promise of siRNA and Chemotherapy Combinations in Cancer Therapies

  2025cites this paper
• Clinical implications of miR-195 in cancer: mechanisms, potential applications, and therapeutic strategies

  2025cites this paper
• Effects of Non-Coding RNAs in Prostate Cancer: Diagnosis, Prognosis, and Therapy

  2025cites this paper
• Influence of PARP1 on CRISPR/Cas9 induced double strand break repair in proliferating cells

  2025cites this paper
• Gene expression silencing therapy in tumors, focus on gastrointestinal and genitourinary tumors

  2025cites this paper
• Novel benzofuran-conjugated indolin-2-ones as anticancer agents; design, synthesis, biological assessments, and molecular modeling insights.

  2025cites this paper
• siRNA-based therapeutics in hormone-driven cancers: Advancements and benefits over conventional treatments.

  2025cites this paper
• Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies.

  2024cites this paper
• USP5 knockdown alleviates lung cancer progression via activating PARP1-mediated mTOR signaling pathway

  2023cites this paper
• Template-Assisted Assembly of Hybrid DNA/RNA Nanostructures Using Branched Oligodeoxy- and Oligoribonucleotides

  2023cites this paper
• Identifying the personalized driver gene sets maximally contributing to abnormality of transcriptome phenotype in glioblastoma multiforme individuals

  2023cites this paper
• Connexin43 is associated with the progression of clear cell renal carcinoma and is regulated by tangeretin to sygergize with tyrosine kinase inhibitors

  2023cites this paper
• Dual-target inhibitors of PARP1 in cancer therapy: a drug discovery perspective.

  2023cites this paper
• PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine.

  2022cites this paper
• HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway

  2022cites this paper
• Targeting the SOX2/PARP1 complex to intervene in the growth of esophageal squamous cell carcinoma.

  2022cites this paper
• DNA damage response and repair in the development and treatment of brain tumors.

  2022cites this paper
• Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy

  2021cites this paper
• Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance

  2021cites this paper
• PARP1 Is Targeted by miR-519a-3p and Promotes the Migration, Invasion, and Tube Formation of Ovarian Cancer Cells

  2021cites this paper
• Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity

  2021cites this paper
• CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway

  2021cites this paper
• Identifying the key genes and microRNAs in prostate cancer bone metastasis by bioinformatics analysis

  2020cites this paper
• Advances in Targeting Cancer-Associated Genes by Designed siRNA in Prostate Cancer

  2020cites this paper
• Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression

  2020cites this paper
• FOXO transcription factor family in cancer and metastasis

  2020cites this paper
• PARP1 (poly(ADP-ribose) polymerase 1)

  2020cites this paper
• Oleanolic Acid Ameliorates Benign Prostatic Hyperplasia by Regulating PCNA-Dependent Cell Cycle Progression In Vivo and In Vitro.

  2020cites this paper
• Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer

  2020cites this paper
• Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.

  2019cites this paper
• Biguanides in combination with olaparib limits tumorigenesis of drug‐resistant ovarian cancer cells through inhibition of Snail

  2019cites this paper
• Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance

  2019cites this paper
• Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer

  2019cites this paper
• Emerging therapeutic targets for patients with advanced prostate cancer.

  2019cites this paper
• Allicin attenuates calcium oxalate crystal deposition in the rat kidney by regulating gap junction function

  2018cites this paper